Ergoteles’s Checkpoint Therapeutics CKPT Stock Holding History

Ergoteles’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15,780	Closed	-$466K	–	1266
2021 Q2	$466K	Buy	+15,780	New	+$437K	0.01%	848

Other funds holding CKPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAG

Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Ergoteles's CKPT Position: Q3 2021 in Review

Ergoteles sold out of Checkpoint Therapeutics (CKPT) in Q3 2021, closing a stake of 15,780 shares — an estimated $466K sold.

Ergoteles first reported a position in CKPT in Q2 2021 and held it in 1 quarter. The position peaked at $466K in Q2 2021. 67 funds tracked by Wall St. Rank hold CKPT as of Q3 2021.

Ergoteles reported no remaining Checkpoint Therapeutics position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 15,780 Checkpoint Therapeutics shares in Q3 2021, an estimated $466K.
Ergoteles first reported a position in Checkpoint Therapeutics in Q2 2021 and held it in 1 quarter.
Ergoteles's Checkpoint Therapeutics position peaked at $466K in Q2 2021.
67 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.